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HIGH DOSE INTERVAL VITAMIN D SUPPLEMENTATION IN PEDIATRIC 
PATIENTS WITH INFLAMMATORY BOWEL DISEASE RECEIVING 
REMICADE 
 
REEDER M. WELLS 
 
ABSTRACT 
BACKGROUND: Patients suffering from inflammatory bowel disease (IBD) are at 
increased risk of vitamin D deficiency. Daily or weekly vitamin D supplementation has 
not proven to be effective in improving vitamin D status, and it is thought that this failure 
has been primarily due to a lack of compliance. Circulating vitamin D is crucial to bone 
growth and development in children and adolescents. However, more recent data has 
demonstrated that vitamin D also plays a significant role in the maintenance and 
regulation of the immune system. 
OBJECTIVES: The primary aim of this study is to investigate the safety and efficacy of 
administering high dose oral vitamin D therapy in pediatric patients with IBD. We chose 
to study patients receiving Remicade, an immunosuppressive monoclonal antibody 
therapy administered intravenously, as the need for scheduled hospital-based infusions 
provides a unique opportunity to ensure compliance in our study population. 
METHODS: We identified consecutive pediatric patients with IBD with a recent 25-
hydroxyvitamin D (25OHD) level < 30ng/mL, maintained on Remicade, and with no 
history of kidney or liver disease for inclusion in the study from November 2017 and 
  vii 
November 2018. Enrolled patients received one-year of open-label therapy. Vitamin D 
treatment doses were assigned by Remicade interval and patients received either 50,000 
international units (IU) (every 4-5 weeks) or 100,000 IU (every 6-8 weeks) vitamin D3 
orally at the time of their Remicade infusions. In addition to vitamin D levels, spot urine 
calcium to creatinine ratios, serum calcium, phosphorus, and blood urea nitrogen (BUN) 
levels, quality of life metrics, and surveys pertaining to dietary vitamin D intake and 
ultraviolet B (UVB) radiation exposure were collected throughout the study period. 
RESULTS: Baseline vitamin D status in enrolled patients did not differ by gender, dosing 
group, diet, or diagnosis (Crohn disease or ulcerative colitis). Subjects reached steady-
state serum 25OHD levels after three doses administered over a span of 4 to 8 months, 
our data demonstrated an increase in average 25OH vitamin D levels from 21.17 ng/mL 
to 28.19 ng/mL in the 50,000 IU and 23.00 ng/mL to 33.18 ng/mL in the 100,000 IU dose 
groups, respectively. The improvement in vitamin D status did not correlate with changes 
in quality of life or disease activity. The response to vitamin D therapy was independent 
of diet, sun exposure, race, gender, diagnosis, or season of enrollment. There were no 
adverse events, including changes in urine calcium to creatinine excretion or serum BUN 
and creatinine values. Several patients manifest a small decrease in serum phosphorus 
during the initial phase of the study. However, these changes were transient and no 
subjects exhibited clinical signs or symptoms of hypophosphatemia. 
CONCLUSION: High dose, interval vitamin D supplementation achieved steady-state 
25OHD levels of 30 ng/mL or greater, with no signs of toxicity in patients enrolled in this 
pilot study. These data suggest that high-dose interval therapy may be a feasible 
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treatment option that bypasses limitations related to difficulties with patient compliance. 
Further studies are necessary to determine optimal dosage regimens and to assess 
endpoints related to immune function and improvements to gastrointestinal health. 
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INTRODUCTION 
Inflammatory Bowel Disease 
 Inflammatory bowel disease (IBD) is a collective term that refers to the chronic 
gastrointestinal (GI) inflammation and damage in patients with Crohn Disease (CD) and 
Ulcerative colitis (UC). CD can result in often discontinuous areas of inflammation that 
can occur in any section of the GI tract, extending from the mouth to the anus. In 
contrast, the inflammation observed in patients with UC typically begins in the rectum 
and extends, in contiguous fashion, to involve part or all of the large intestine. The 
inflammation in patients with CD is often transmural, and can extend to involve the 
whole wall of the intestine, while the inflammatory response in patients with UC is 
limited to the superficial lining of the large intestine. Patients with IBD typically present 
with a spectrum of GI-related and systemic symptoms including abdominal discomfort, 
fatigue, nausea, weight loss, fever, and anemia, all of which contribute to an overall 
decreased in quality of life (NIDDKa, n.d.; NIDDKb, n.d.). Similar to other chronic 
autoimmune or idiopathic inflammatory diseases like asthma, arthritis, and psoriasis, 
there is no cure for IBD. Instead, current treatment strategies are aimed at symptom 
relief, controlling inflammation, and preventing development of end-stage complications 
including fistulas, perforation, or impaired growth and development (NIDDKc, n.d.). 
The prevalence of CD and UC among commercially insured pediatric patients in 
the U.S. has been estimated at 57.8 and 33.9 per 100,000, respectively. There appears to 
be an increased incidence of CD in the Northeast and Midwest regions, relative to the 
South and West regions (Table 1), and this has contributed to the hypothesis that average 
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exposure to sunlight may impact IBD prevalence or phenotype (Kappelman, Moore, 
Allen, & Cook, 2013a). Vitamin D deficiency has also been correlated with darker skin 
complexion, the winter months, and upper GI inflammation in CD (Pappa et al., 2006a). 
Data from related studies has supported what appears to be a strong association between 
IBD and vitamin D deficiency, with higher incidence of vitamin D deficiency (25OHD < 
20ng/mL) or insufficiency (25OHD < 30 ng/mL) in patients with IBD than in control 
populations ( Pappa et al., 2006a; Ahlawat, Weinstein, & Pettei, 2017). This has led to 
increased monitoring of vitamin D levels in IBD patients. Though these findings have 
raised awareness concerning vitamin D status in this disease population, most centers 
report only a 52.3% rate of compliance with at-home supplementation (Lewis et al., 
2013). 
Table 1. Prevalence of Pediatric IBD in the U.S. Incidence of CD and UC per 100,000 
pediatric patients. Recorded by region in the U.S. from 2008 to 2009; adapted from 
(Kappelman, Moore, Allen, & Cook, 2013b). 
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Vitamin D Deficiency 
 The role of vitamin D in calcium homeostasis and its relationship to bone diseases 
such as rickets and osteoporosis have long been established. However, the discovery of 
vitamin D receptor (VDR) expression in tissues outside of the bone/calcium axis has 
implicated vitamin D in the regulation of innate and adaptive immune responses ( Yin & 
Agrawal, 2014a; Looman Kirsten I.M. et al., 2017). 25OHD is produced in the liver as a 
derivative of vitamin D2 /D3 obtained from dietary sources, in which they are absorbed in 
the small intestine and enter the circulation via the lymphatic system, and endogenously 
produced in the skin in response to exposure to UVB catalysis from sunlight. Once in 
circulation, the lipid soluble 25OHD is able to freely diffuse into tissue compartments, 
such as the kidneys, where vitamin D sensitive cells expressing 25OHD 1α-hydroxylase 
(CYP27B1) convert the vitamin to its active form, 1,25-dihydroxyvitamin D 
(1,25(OH)2D), which subsequently interacts with nuclear VDR’s (Yin & Agrawal, 
2014a). The binding of 1,25(OH)2D to VDR in dendritic cells and T lymphocytes has 
been shown to have a net immunosuppressive effect, acting to suppress dendritic cell 
activation of lymphocytes, both directly, and by releasing cytokines, such as interleukin-
10 (IL-10), that promote immunosuppressive T regulatory cell differentiation, and 
directly inhibiting T cell release of proinflammatory signals (Figure 1). 
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Figure 1. Immunosuppressive Action of Vitamin D on the Adaptive Immune 
Response. 1,25(OH)2D binding to nuclear VDR following CYP27B1 activation of 
25OHD works to 1) deactivate dendritic cells, 2) promote T regulatory cell (Treg cells) 
differentiation via IL-10, and 3) inhibits T cell production and release of proinflammatory 
cytokines; adapted from (Yin & Agrawal, 2014a). 
 
 There is strong evidence from murine models that the actions of 1,25(OH)2D and 
its cognate receptor (VDR) in the gut mucosa can play a significant role in mediating 
colonic inflammation. The expression of human VDR in murine intestinal epithelial cells 
was found to be protective against chemically induced and T cell transfer induced models 
of colitis, as well as able to rescue VDR knockout mice from colonic injury and 
inflammation  (Liu et al., 2013). Mechanistically, it has been demonstrated that the lack 
of functional VDR signaling in VDR/IL-10 knockout mice leads to defective autophagy 
in the intestinal epithelium, altered Paneth cell function, and shifts in the microbiome 
composition toward dysbiosis and the development of colitis (S. Wu et al., 2015). While 
animal models of colitis point to a protective role of circulating 25OHD, support for an 
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analogous role in human disease is still lacking. Nonetheless, epidemiological studies 
have identified an inverse relationship between total 25OHD and intestinal inflammatory 
markers. Data from other studies has suggested that free/bioavailable vitamin D (which 
only represents about 5-10% of total circulating 25OHD levels), is relevant in regulating 
inflammation in newly diagnosed pediatric patients with UC (Garg, Rosella, Lubel, & 
Gibson, 2013; Sauer et al., 2018). Another study found vitamin D status to be predictive 
of duration of response to anti-tumor necrosis factor  (TNF) therapy in patients with 
IBD, citing that patients with insufficient vitamin D levels (< 30 ng/mL) experienced 
earlier therapy cessation than patients who were vitamin D sufficient (Zator et al., 2014). 
In the general population, 25OHD levels greater than 40 ng/mL have been associated 
with a decreased risk of colon and colorectal cancers (K. Wu et al., 2007; Jenab et al., 
2010), for which children with IBD are already susceptible (Olén et al., 2017). 
Conclusions regarding the clinical significance of vitamin D beyond bone 
homeostasis is further complicated by differing definitions of vitamin D insufficiency and 
deficiency. A 2014 global, evidence-based consensus on the clinical management of 
nutritional rickets in children considers a serum 25OHD > 20ng/mL to be sufficient for 
turning off parathyroid hormone and protecting from adaptive hyperparathyroidism in the 
development of rickets (Munns et al., 2016). However, it has been suggested that serum 
25OHD levels of 30-40 ng/mL are desirable for decreasing the risk of colorectal cancer in 
adult populations (McCullough et al., 2018). 
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Vitamin D Supplementation 
Vitamin D is involved in multiple body systems, is derived from more than one 
source, and has a highly regulated metabolic pathway. As such, it is difficult to accurately 
assess the impact of any single intervention on circulating 25OHD levels. For example, 
higher rates of vitamin D deficiency and insufficiency have also been associated with 
obesity (Pereira‐Santos et al., 2015). This is likely due to the high lipid solubility of 
vitamin D and obesity resulting in a much greater volume of distribution. Serum 25OHD 
levels can also vary based on the time of the year measurements were taken. One cross-
regional, multi-year analysis of serum 25OHD measurements found that, on average, 
vitamin D levels display peak levels early in the Fall, about four weeks after maximal sun 
exposure, and are at their lowest in the early Spring, about four weeks after the winter 
solstice (Kroll et al., 2015a). Despite this annual cycle, recommendations from the FDA 
and the Institute of Medicine include a year-round dietary intake of 600 IU of vitamin 
D/day for children over the age of four, with vitamin D supplementation not to exceed 
4000 IU/day (Institute of Medicine, 2011). 
Although there are two forms of vitamin D, D2 and D3, vitamin D3 has a greater 
affinity for the vitamin’s carrier, vitamin D-binding protein (DBP), and has demonstrated 
a greater ability to influence the clinical indicator of vitamin D status, serum 25OHD 
(Armas, Hollis, & Heaney, 2004; Logan et al., 2013; Yin & Agrawal, 2014a). A one-time 
100,000 IU dose of vitamin D3 was shown to achieve peak 25OHD levels at one week 
after administration before 25OHD levels slowly returned to pretreatment levels over the 
next 12 weeks (Ilahi, Armas, & Heaney, 2008). While this single dose pharmacokinetic 
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study was able to achieve an average peak serum 25OHD level > 40.0ng/mL, a 15 ng/mL 
increase from pretreatment 25OHD levels, in subjects receiving just one dose of vitamin 
D3, it is notable that 7% of subjects never attained a serum 25OHD level above 32.0 
ng/mL. This latter observation could be explained by genetic heterogeneity among the 
enzymes and regulatory proteins involved in vitamin D metabolism. 
 The presence of small nucleotide polymorphisms in the CYP2R1 gene that 
encodes for 25OHD 25-hydroxylase, the enzyme responsible for converting D2 and D3 
into 25OHD in the liver, has been implicated in the differential response to vitamin D 
supplementation. Patients found to have a lower activity polymorphism in the CYP2R1 
gene were less responsive to vitamin D3 supplementation, measured by change in serum 
25OHD, relative to those patients without the polymorphism (Lewis et al., 2013). 
 
Remicade (Infliximab) Infusions 
IBD is a chronic GI inflammatory disease for which there is currently no cure. 
Pharmaceutical treatments focus on maintaining remission with oral or intravenous 
immunosuppressive and anti-inflammatory therapies, either as monotherapy or in 
combination. Infliximab, brand named Remicade (BLA 103772), is a chimeric 
monoclonal antibody that acts in circulation as a tumor necrosis factor- (TNF) 
antagonist. The antagonism results in attenuated immune cell proliferation, induction of 
as well as increased apoptosis in TNF-secreting regulatory lymphocytes. Remicade 
presently holds FDA indication for treatment of Crohn disease and ulcerative colitis in 
both adult and pediatric patients 6 years and older who have not responded to other 
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therapies (Janssen Biotech, Inc., 2017). Patients receiving Remicade typically come in for 
infusions every four to eight weeks (Hyams et al., 2007). In most centers, lab work 
including complete blood cell count and blood chemistries are obtained at the time of 
each infusion. 
 
Objectives 
The aims of this study are to investigate the safety and efficacy of interval high-
dose oral vitamin D supplementation in the treatment of vitamin D deficiency in pediatric 
patients with IBD. A secondary aim of the study is to explore the relationship between 
changes in serum 25OHD levels and clinical and biochemical markers of disease. Based 
on findings, this study will provide preliminary data that can be used to design and power 
larger and more definitive studies to assess the utility of interval vitamin D 
supplementation in pediatric patients with IBD. 
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METHODS 
Screening 
 Patients carrying a diagnosis of IBD (CD, UC, or indeterminate colitis), followed 
in the Division of Gastroenterology at Boston Children’s Hospital (BCH), and treated 
with Remicade were identified using the hospital electronic medical record. A subsequent 
chart review included abstraction of each patient’s vitamin D status. Patients without a 
recorded serum 25OHD level later than October 1, 2016 were excluded from the study. 
Patients with a serum 25OHD > 30ng/mL were considered vitamin D sufficient and not 
considered currently eligible for the study. However, the serum 25OHD levels of vitamin 
D sufficient patients were re-evaluated each time there was an additional 25OHD level 
measured up until November 31, 2018. Patients with a serum 25OHD level < 30 ng/mL 
were classified as being vitamin D insufficient, but were only eligible to enroll if the date 
of approach/consent was within 8 weeks of the patient’s most recent 25OHD level. 
 Patients were deemed ineligible if there was any history of granulomatous disease 
or deficits in kidney/liver function that might confound the evaluation of safety measures 
and vitamin D metabolism. Patients were also excluded for dysphagia, age > 25 years-
old, and at the discretion of their primary GI provider. 
 
Recruitment 
 Patients deemed eligible were approached for consent at a clinically scheduled 
Remicade infusion or GI outpatient follow-up appointment. Study patients were 
consented and enrolled after the goals, as well as the risk and benefits of the study were 
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discussed with patients and/or their guardian(s) and they had every opportunity to ask 
relevant questions. 
 
High Dose Vitamin D Supplementation 
 Upon enrollment, patients were assigned to the 50,000 IU dose group if their 
clinical plan called for Remicade infusions every 4 to 5 weeks or to the 100,000 IU dose 
group if their clinical plan called for Remicade infusions at intervals of six to eight 
weeks. Patients were administered either one capsule (50,000 IU dose group) or two 
capsules (100,000 IU) of vitamin D3 at their next Remicade infusion, deemed “Infusion 
1,” and each subsequent Remicade infusion thereafter for about one year. 
 The D3-50 50,000 IU vitamin D3 capsules (Bio-Tech Pharmacal, Inc., 
Fayetteville, AR) were used for supplementation. Other ingredients included 
microcrystalline cellulose and gelatin. 
 
Survey and Lab Data 
 Patients were asked to fill out the IMPACT-III instrument, a 35-item health-
related quality of life (HRQoL) assessment for pediatric patients with IBD (Griffiths et 
al., 1999; Ogden et al., 2008). At Infusion 1, the date of first high dose vitamin D 
administration, patients were asked to fill out a baseline survey (Appendix A) for use in 
estimating a particular patient’s average sunlight/UVB exposure and dietary vitamin D 
intake. The electronic medical record was also used to abstract the most recent 
assessment of clinical disease activity, recorded as either Abbreviated Pediatric Crohn 
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Disease Activity Index (aPCDAI) or Pediatric Ulcerative Colitis Activity Index (PUCAI) 
scores (Turner et al., 2007; Kappelman et al., 2011), surgical history, relevant diagnostic 
studies, and concurrent medications. At each subsequent infusion (typically administered 
every 4 to 8 weeks), patients filled out a follow-up survey (Appendix B) to assess extra-
supplemental sources of vitamin D. At each infusion, anthropomorphic measures, 
changes in concurrent medications, clinical care updates, and hematology and blood 
chemistry labs, that make up care for all patients receiving Remicade, were collected 
(Table 2). 
 A serum 25OHD and spot urine calcium to creatinine ratio (Ca/Cr) was 
determined at every other infusion to evaluate efficacy and to monitor for hypercalciuria 
(Jones et al., 2012), respectively. If a patient was found to have an elevated spot urine 
calcium to creatinine ratio (Ca/Cr >0.200), a follow-up spot Ca/Cr was ordered to be 
completed at the time of their next infusion (four to eight weeks later). If a patient was 
observed to have two subsequent spot Ca/Cr ratios >0.200, a 24-hour urine collection was 
ordered, Ca/Cr calculated, and the propriety of continued participation in the study was 
assessed. 
 Between 48 and 64 weeks after first high dose administration (Infusion 12 for the 
50,000 IU dose group and Infusion 8 for the 100,000 IU dose group), patients were asked 
to again fill out the IMPACT-III healthy related quality of life survey and disease activity 
was evaluated using the aPCDAI or PUCAI scores (Table 2). 
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Table 2. Data collection schedule. Subjects were followed for 48-64 weeks, depending 
on duration between intervals. Subjects receiving 100,000 IU dose completed study at 
Infusion 8 while those receiving 50,000 IU were followed until Infusion 12. When 
appropriate, date of consent was concurrent with Infusion 1. 
 
Item 
Date of 
Consent 
1 
 
2 3 4 5 6 7 8 9 
50K 
only 
10 
50K 
only 
11 
50K 
only 
12 
50K 
only 
Consent Form X             
IMPACT-III 
(HRQoL) 
X        
X 
100K 
only 
   
X 
Baseline 
Survey 
 X            
Clinical Care 
Labs 
 X X X X X X X X X X X X 
Follow Up 
Surveys 
  X X X X X X X X X X X 
High Dose 
Vitamin D3 
 X X X X X X X X X X X X 
Serum 
25OHD 
  X  X  X  X  X  X 
Spot Urine 
Ca/Cr ratio 
  X  X  X  X  X  X 
 
Data Collection and Analysis 
Abstracted laboratory and clinical data were transferred into Case Report Forms 
created on Research Electronic Data Capture (REDCap), a Health Insurance Portability 
and Accountability Act of 1996 (HIPAA)-compliant web application. Data exported from 
REDCap was then analyzed in R Studio, an open-source computing and graphics 
platform.  
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RESULTS 
Enrollment 
 A total of 512 pediatric patients with IBD receiving Remicade were screened for 
serum 25OHD status between October 2017 and November 2018. 386 (75.4%) had serum 
25OHD levels measured between October 1, 2016 and November 31, 2018. Of these, 188 
(48.7%) had serum 25OHD levels > 30ng/mL and were considered vitamin D sufficient. 
Of the 198 (51.3%) patients with serum 25OHD levels < 30ng/mL, 46 (23.7%) were 
ineligible to approach due to the lack of a 25OHD level that would be within 8 weeks of 
the date of consent. Screening for pre-existing liver, kidney, and granulomatous disorders 
excluded 14 patients, leaving 134 patients eligible to approach. 77 (56.7%) of these 
patients would be available for the expected duration of the study, were deemed 
appropriate for the study by their primary GI providers, and were approached, 8 declined 
and 69 were consented. However, 3 patients were unable to swallow the study capsules 
and 1 was found to be allergic to gelatin, an inactive ingredient in the capsule 
formulation. These 4 patients were not enrolled. Of the 65 patients enrolled, 4 were 
excluded for noncompliance with Remicade infusions or inconsistently taking study 
capsules, 2 were withdrawn by their providers in order to return to prescribed 
supplementation, 1 opted to withdraw from the study as a result of nausea that they 
experienced in conjunction with vitamin D3 dosing, 4 patients were either transferred to 
adult care or switched to a maintenance medication other than Remicade, and 1 patient 
lost to follow-up, resulting in final enrollment of 53 patients (Figure 2).  
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Figure 2. Subject 
Screening and 
Recruitment. A total of 
512 patients receiving 
regular Remicade 
infusions for IBD at BCH 
were screened for vitamin 
D status and study 
eligibility between Oct. 
2017 and Nov. 2018. A 
total of 65 patients were 
enrolled, 12 were excluded 
post-enrollment to give 
final enrollment of 53 
subjects. 
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Demographics 
65 patients were enrolled, but 5 patients were removed from the study before 
completing the baseline surveys or receiving a second dose and 7 were either 
retroactively removed or lost to follow up after receiving 3 or more doses. Therefore, 
baseline and dose response data were available from 60 subjects in both dosing groups. 
 The total enrolled subject population was 68% male, distributed similarly in the 
50,000 IU (66.72% male) and 100,000 IU (70.7% male) dose groups, with an average age 
of 16.50 ± 3.83 years at time of consent. The 50,000 IU was slightly younger (15.00 ± 
4.59 years) than the 100,000 IU (17.14 ± 3.32 years), and the total subject population had 
an average body mass index (BMI) of 23.9 ± 5.7 kg/m2 at time of consent. The majority 
of study subjects identified as White (70%), 21.7% identified as Other, 6.7% as Black, 1 
subject identified as Asian, and 1 as Native American. This distribution was similarly 
reflected in each dosing group. 45 (75%) of the enrolled subjects carried a diagnosis of 
CD, 14 (23%) of UC, and 1 subject was classified as having indeterminate colitis. All 
patients participating in the study received regular Remicade infusions as a maintenance 
therapy for IBD and for 26 (43.3%) this was their only maintenance therapy. 22 (36.7%) 
patients were prescribed an immunomodulator as adjunctive therapy (either methotrexate 
or mercaptopurine), 4 (6.7%) took an aminosalicylate adjunct, 3 (5%) were currently 
prescribed steroids at time of consent, and 5 (8.3%) were treated with a combination of 
two or more of these therapies. The 100,000 IU dose group had more subjects not on 
additional IBD therapies (48.8%) and less multiple adjunctive therapies (2.4%) in relation 
to the 50,000 IU dose group, 31.6% and 21.1%, respectively (Table 3). 
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Table 3. Demographics and Descriptive Characteristics. Description of the 60 patients 
enrolled in the study who completed baseline data and received 3 or more doses of high 
dose supplementation, separated by dose group. 
 
 50,000 IU dose 
group 
100,000 IU dose 
group 
Total 
Gender 
Male 
Female 
 
12 (66.7%) 
6 (33.3%) 
 
29 (70.7%) 
13 (31.7%) 
 
41 (68%) 
19 (32%) 
Age (years) 
At time of consent 
15.00 ± 4.59 17.14 ± 3.32 16.50 ± 3.83 
Ethnicity 
White 
Black 
Asian 
Native American 
Other 
 
12 (63.1%) 
1 (5.3%) 
0 
1 (5.3%) 
5 (26.3%) 
 
 
30 (73.2%) 
3 (7.3%) 
1 (2.4%) 
0 
8 (19.5%) 
 
42 (70.0%) 
4 (6.7%) 
1 (1.7%) 
1 (1.7%) 
13 (21.7%) 
 
Diagnosis 
CD 
Inflammatory 
Penetrating 
Stricturing 
Unknown 
UC 
Proctitis 
Left-sided 
Pancolitis 
Indeterminate colitis 
 
 
14 (73.7%) 
8 
1 
3 
0 
5 (26.3%) 
0 
1 
4 
1 (5%) 
 
33 (80.5%) 
23 
2 
5 
3 
9 (22.0%) 
0 
2 
7 
0 
 
45 (75.0%) 
31 
3 
8 
3 
14 (23.3%) 
0 
3 
11 
1 (1.7%) 
Concurrent IBD 
Medications 
Immunomodulator 
Aminosalicylates 
Steroids 
≥2 of the above 
Remicade only 
 
 
 
7 (36.8%) 
1 (5.3%) 
0  
4 (21.1%) 
6 (31.6%) 
 
 
15 (36.6%) 
3 (7.3%) 
3 (7.3%) 
1 (2.4%) 
20 (48.8%) 
 
 
22 (36.7%) 
4 (6.7%) 
3 (5.0%) 
5 (8.3%) 
26 (43.3%) 
BMI (kg/m2) 
At time of consent 
25.0 ± 5.0 23.5 ± 5.9 23.9 ± 5.7 
Baseline serum 25OHD 
(ng/mL) 
21.17 ± 5.70 23.00 ± 4.07 22.45±4.67 
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Vitamin D Status 
 All patients enrolled had been identified as vitamin insufficient or vitamin D 
deficient as part of recruitment screening and had recent total 25OHD levels of less than 
30 ng/mL. The average pretreatment serum 25OHD level for male subjects (21.73 ± 4.91 
ng/mL) was not shown to differ from that of female subjects (24.00 ± 3.73 ng/mL) by an 
unequal variance t-test (t, -1.97; confidence interval [CI], -4.58 – 0.05; p = 0.06). 
Unequal variances t-test also did not suggest a difference in pretreatment vitamin D status 
between patients with CD and UC, 22.22 ± 4.74 and 23.02 ± 4.68 respectively (t, -.056; 
CI, -3.78 – 2.17; p = 0.58). A one-way ANOVA of subjects’ responses to survey 
questions showed differences in the baseline 25OHD level based on racial identification 
(F[1, 55]= 6.77; p< 0.001), with visualization of this data showing that subjects who 
identified as ‘Other’ had, on average, lower baseline 25OHD levels than those who 
identified as ‘White,’ ‘Black or African American,’ ‘Asian,’ ‘Native Hawaiian or Pacific 
Islander,’ or ‘American Indian or Alaskan Native.’ The severity of vitamin D deficiency 
was not shown to correlate with age (Pearson R [R], -1.24; CI, -0.36 – 0.13; p = 0.34), 
BMI (R, -0.09; CI, -0.34- 0.16; p = 0.46), or inclusion of dairy, vitamin D fortified 
cereals, and fish in the diet (R, -0.07; CI, -0.33- 0.21; p = 0.64) in this vitamin D 
deficient/insufficient population. In regards to skin exposure to sunlight and UVB 
radiation, baseline vitamin D levels appeared independent of reported sun sensitivity 
(F[1, 55]= 0.60; p= 0.44) and time spent outside on a typical day (R, -0.02; CI, -0.28- 
0.25; p= 0.90). However, increased skin exposure to the sun, reported as daily typical 
clothing coverage and ranging from just head and neck to “bathing suit” exposure, was 
  18 
positively correlated with total 25OHD levels among vitamin D deficient patients (R, 
0.44; CI, 0.20 – 0.63; p > 0.001). Although seasonal variation in serum 25OHD levels has 
been demonstrated in populations living at higher latitudes (Kroll et al., 2015b), there was 
no observed difference in baseline 25OHD level based on the month of treatment 
initiation (F[9, 50]= 1.345; p = 0.24).  
All 60 patients were treated, or are currently being treated, according to the 
supplementation protocol at their Remicade infusions for one year. Both dosing groups, 
on average, reached steady state serum 25OHD levels after administration of three doses, 
which was about four to eight months after the start of therapy, and therefore total 
25OHD measured at infusion 4 was designated the steady-state level (Figure 3). Steady-
state serum 25OHD levels were 28.91 ± 5.60 ng/mL and 33.18 ± 5.80 ng/mL for the 
50,000 IU and 100,000 IU dosing groups, respectively. In general, total serum 25OHD 
levels were increased from baseline levels in both the 50,000 IU dosing group (t, 6.932; 
CI, 5.20 – 9.79; p < 0.01) and the 100,000 IU dosing group (t, 8.722; CI, 7.72 – 12.41; p 
< 0.01) by paired t-test analysis. The 25OHD increase from baseline was 7.74 ng/mL in 
50,000 IU dose group and 10.18 ng/mL in 100,000 IU dose group, but these changes 
were not found to be statistically different (t, -1.626; CI, -5.76 – 0.61; p = 0.11). This 
change in vitamin D status was found to be similar between CD and UC patients (t, -
1.398; CI, -8.29 – -1.79; p= 0.19) and between genders (t, 1.60; CI, -0.63- 5.50; p = 0.12).
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Figure 3. Effect of high dose therapy on serum total 25OHD. 60 patients were treated 
with high doses oral vitamin D3 concurrent with Remicade infusions for approximately 
one year. A steady state 25OHD level was achieved after 3 doses was achieved in both 
the 50,000 IU dosing group (top) and the 100,000 IU dosing group (bottom). 
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Data from recent studies on vitamin D status in adults with IBD suggests that 
achieving total circulating 25OHD levels in the 30-40ng/mL range can be protective 
against colon cancer. By infusion 4 of the study, a total of 31 (61%) of subjects had 
achieved total 25OHD ≥ 30 ng/mL and were considered to be vitamin D sufficient. The 
percentage of subjects achieving target range 25OHD levels at steady state did not differ 
by dosing group: 8 subjects (47%) receiving 50,000 IU doses reached 25OHD ≥ 30ng/mL 
in 16 to 20 weeks, and 23 subjects (68%) receiving 100,000 IU doses achieved steady 
state 25OHD levels ≥ 30ng/mL in 24 to 48 weeks (2[1, N=51] = 1.24; p = 0.26). There 
was neither a difference in response with respect to the different types of IBD, as 21 
(52.5%) subjects and 9 (90%) subjects achieved sufficient 25OHD at steady state with 
CD and UC, respectively (2[1, N=50] = 3.25; p= 0.07), nor a difference between genders 
(2[1, N=51] = 0.06; p = 0.81). 
Throughout the course of the study, each subjects’ clinical course, lab values, 
medication changes, diet, and seasonal sun exposure were observed in order to determine 
extra-supplemental factors that might also influence total 25OHD. The time of year was 
not found to affect steady state 25OHD levels achieved (F [8, 42] = 1.062; p = 0.41) or 
change in 25OHD from baseline to steady-state (F [8, 42] = 1.193; p =0.33) (Figure 4). 
In addition to tracking vitamin D status, blood chemistry and inflammatory markers 
measured as part of patients’ standard clinical care were also monitored to assess safety 
and efficacy. 
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Figure 4. Effect of the season of therapy initiation on total 25OHD levels. Subjects 
were started on high dose therapy within 8 weeks of baseline 25OHD level throughout 
the year. The month of therapy initiation was not found to influence baseline levels, nor 
was it found to affect steady-state levels, defined as 25OHD level at Infusion 4, or change 
in 25OHD from baseline to steady-state. 
 
 In addition to monitoring seasonal effects, survey data were collected throughout 
the study to assess extra-supplementation sources of vitamin D, most notably diet and sun 
exposure. Total change in serum 25OHD between was not shown to correlate with age or 
BMI for either dosing group. There was also no demonstrated influence of race, self-
reported sun sensitivity, hours spent outside, or areas of skin exposure on serum 25OHD 
in patients receiving high dose supplementation. Reported consumption of vitamin D rich 
foods, such as dairy, vitamin D fortified cereals, and fish was not shown to correlate with 
changes in total 25OHD from baseline in the 100,000 IU dosing group (Table 4). The 
effect of diets in the 50,000 IU group remains undetermined due to low sample size. 
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Table 4. Effect of External Factors Affecting Vitamin D Status and Therapy 
Response. Vitamin D status can be influenced by a multitude of factors including dietary 
(exogenous) intake, UVB catalyzed production (endogenous), body composition, and 
liver and kidney function. Data was collected from patients on dietary intake and UVB 
radiation exposure throughout the study to assess their influence on total 25OHD. *Low 
sample size, n= 3 
 
 50,000 IU     100,000 IU    
 
Pearson R 95% CI F 
value 
p- 
value 
 
Pearson R 95% CI F 
value 
p-
value 
Age 
(years) 
0.18 -0.33 to 0.61   0.50 
 
-0.12 -0.44 to 0.23 
 
0.50 
BMI 
(kg/m2) 
0.01 -0.50 to 0.49   0.96 
 
-0.09 -0.42 to 0.26 
 
0.61 
Self-
identified 
race 
    1.01 0.42 
   
0.56 0.65 
Relative 
dietary 
Vitamin D  
0.93* 
 
  0.24 
 
-0.21 -0.6 to 0.29 
 
0.41 
Self-
reported 
sun 
sensitivity 
(Hi, Med, 
or Lo) 
    0.01 0.92 
   
0.05 0.82 
Time spent 
outside 
(hrs/day) 
0.50 -0.02 to 0.80   0.06 
 
0.25 -0.12 to 0.56 
 
0.17 
Skin area 
exposed to 
the sun 
(relative 
clothing 
coverage) 
-0.22 -0.66 to 0.33   0.43 
 
0.37 0.01 to 0.64 
 
0.05 
 
Safety 
 Blood chemistry labs were traced to assess for the emergence of side effects that 
could be related to interval high dose vitamin D treatment, particularly hypercalcemia 
and risk of kidney stones. Blood chemistry labs remained unchanged through four 
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administered doses in the 50,000 IU dosing group, and no change from baseline was 
detected in serum calcium (F[3, 39] = 0.23; p = 0.87), creatinine (F[3, 39] = 1.54; p = 
0.22), phosphorus (F[3, 39] = 0.33; p = 0.81) or BUN (F[3, 39] = 0.60; p = 0.62) by one-
way repeated measures analysis of variance. The 100,000 IU dosing group also saw no 
change in calcium (F[3, 87] = 0.35; p = 0.79), creatinine (F[3, 87] = 1.86; p = 0.14), or 
BUN (F[3, 87] = 0.18; p = 0.91) lab values. However, a fall in serum phosphorus levels 
(F[3, 78] = 3.52; p = 0.02) was observed by the fourth dose in 100,000 IU dose group 
(Table 5). Spot urine samples were also collected to assess the risk of hypercalciuria and 
the development of kidney stones while on high dose supplementation. 
Table 5. Blood chemistry to assess therapy safety. Blood chemistry labs were observed 
to monitor occurrence of hypercalcemia or other vitamin D metabolism disturbances as a 
result of therapy. There was no remarkable effect of high dose therapy on CHEM10 
levels. 
 
             
mg/dL 
Baseline Infusion 2 Infusion 4 Infusion 6 Infusion 8 Infusion10 Infusion12 
50K        
  Calcium 9.26± 0.45 9.25± 0.19 9.19± 0.25 9.31± 0.20 9.35± 0.34 9.30±0.46 9.18±0.35 
Creatinine 0.63± 0.24 0.62± 0.21 0.62± 0.22 0.63± 0.19 0.67± 0.21 0.66±0.18 0.51±0.09 
Phosphorus 3.82± 0.64 3.95± 0.81 3.78± 0.87 3.85± 0.77 3.91± 0.90 3.99±0.68 4.33±0.49 
BUN 11.5± 5.3 10.9± 3.7 11.2± 2.7 10.4± 3.7 9.7± 2.8 10.8±1.8 11.8±1.8 
100K        
Calcium 9.34± 0.33 9.30± 0.33 9.33± 0.27 9.37± 0.34 9.48± 0.25 -- -- 
Creatinine 0.71± 0.17 0.71± 0.17 0.73± 0.19 0.74± 0.17 0.76± 0.22 -- -- 
Phosphorus 3.78±0.57* 3.81±0.50* 3.53±0.57* 3.69±0.51 3.94±0.57 -- -- 
BUN 11.6± 3.9 12.2± 4.4 11.5± 3.7 12.2± 3.8 11.0± 2.4 -- -- 
 
  
 While spot urine calcium to creatinine ratio was not collected at baseline, urine 
Ca/Cr’s were measured for the duration of therapy to monitor occurrences of 
hypercalciuria. The average urine Ca/Cr for both dosing groups did not exceed 0.200 
once steady state 25OHD levels had been achieved, and beyond. One-way repeated 
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measures analysis of variances did not suggest any change in urine calcium to creatinine 
ratios in the 50,000 IU dosing group (F[2, 30] = 0.02; p = 0.98) or the 100,000 IU dosing 
group (F[2, 38] = 2.32; p = 0.11) up to and after reaching steady state 25OHD levels, 
from the second through the sixth infusions (Figure 5). However, it is noted that, of the 
subjects with spot Ca/Cr ratios up to infusion 6, there were 1 and 5 urine Ca/Cr ratios 
considered abnormal (>0.200) in the 50,000 IU dosing group and 100,000 IU dosing 
group, respectively (Table 6). 
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Figure 5. Effect of high dose therapy on urine calcium to creatinine ratios. Spot urine 
calcium to creatinine ratios were measured for the duration of high dose therapy in to 
monitor patient risk for hypercalciuria and renal stones. Mean Ca/Cr ratios were well 
below safety threshold (0.2) for both the 50,000 IU dosing group (top) and the 100,000 
IU dosing group (bottom) throughout the study. 
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Spot urine Ca/Cr ratios were collected at every other Remicade infusion while 
patients were on the study to monitor patient risk of hypercalciuria as a result of vitamin 
D therapy. Follow-up urine samples were requested if a measured Ca/Cr was greater than 
0.200 and a subsequent 24-hour urine collection was performed if both spot urine Ca/Cr 
ratios were greater than 0.200. Of the 60 patients who received three or more doses as 
part of the study, 10 (17%) had at least one measured urine Ca/Cr ratio > 0.200 and 5 
(8%) had an elevated follow up Ca/Cr at a subsequent infusion. These 5 patients were 
then subject to 24-hour urine collections, all of which returned normal calcium to 
creatinine ratios (Table 6). There were no instances of kidney stones or signs of kidney 
dysfunction during the study period. 
Table 6. Incidence of elevated urine calcium. Spot urine calcium/creatinine ratios taken 
over time were categorized as either “Normal” (≤0.200) or “Elevated” (>0.200). Subjects 
who recorded an elevated urine Ca/Cr had a follow up spot urine sample measured at 
their next infusion. 
 
 Infusion 2 Infusion 4 Infusion 6 Infusion 8 TOTAL 
50,000 IU # OF SUBJECTS (%)     
Normal 14 (100%) 15 (94%) 15 (94%) 13 (100%) 57 (97%) 
Elevated 0 (0%) 1 (6%) 1 (6%) 0 (0%) 2 (3%) 
Elevated follow-up -- 0 (0%) 0 (0%) -- 0 (0%) 
100,000 IU # OF SUBJECTS (%)     
Normal 32 (91%) 27 (84%) 23 (88%) 9 (90%) 91 (88%) 
Elevated 3 (9%) 5 (16%) 3 (12%) 1 (10%) 12 (12%) 
Elevated follow-up 0 (0%) 2 (6%) 1 (4%) 0 (0%) 3 (3%) 
 
No adverse events were observed during the study in regards to vitamin D 
therapy, nor did any enrolled subjects experience Remicade infusion reactions while on 
the study. It was noted that one consented patient had reported nausea with vitamin D 
  27 
supplementation in the past and removed themselves from the study after experiencing 
similar symptoms upon their first dose. However, no such symptoms were reported by 
enrolled subjects for the remainder of the study. 
 
Disease Activity 
 Baseline disease activity data was collected from 60 patients, including the 
subject’s most recent aPCDAI or PUCAI, for patients with CD and UC, respectively. 44 
patients with CD and all 14 UC patients had disease activity assessed within 8 weeks of 
their qualifying serum 25OHD level and before administration of the first study dose 
(disease activity metrics were not collected for patients with indeterminate colitis as 
aPCDAI or PUCAI were not applicable). 39 (88.6%) of subjects with aPCDAI data were 
classified as having inactive disease (aPCDAI < 10). Baseline serum 25OHD was 22.27 ± 
4.77ng/mL in CD patients with inactive disease and 20.32 ± 4.38ng/mL in patients with 
mild or moderate-to-severe disease, respectively. An inverse correlation was observed 
between 25OHD levels and aPCDAI disease activity scores in this population with CD 
(R, -0.34; CI, -0.58 – -0.05; p= .02). Nine (64.3%) of subjects with UC had disease that 
was classified as being in remission (PUCAI< 10). Baseline serum 25OHD was 22.00 ± 
5.64ng/mL in UC patients in clinical remission and 20.20 ± 6.81ng/mL in patients with 
mild, moderate, or severe disease. No significant correlation was found between 25OHD 
levels and PUCAI scores in subjects with UC (R, -0.28; CI, -0.71 – 0.29; P= 0.33). 
 As of February 1st, 2019, there were 12 subjects with CD, 4 subjects with UC, and 
1 subject with Indeterminate colitis who had completed the one-year treatment protocol 
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and had available disease activity metrics available within 8 weeks of last vitamin D 
dose. Paired t-test analysis of disease activity scales, as reported by primary GI providers 
at follow up appointments, did not demonstrate any change in aPCDAI scores (t, 0.80; 
CI, -1.44 – 3.11; p= 0.44) for CD patients or any change in PUCAI scores (t, -1.57; CI, -
11.37 – 3.87; p= 0.21) in UC patients. Observation and analysis of endpoint disease 
activity metrics will continue as more patients complete the study. 
 In addition to the starting point and endpoint disease activity metrics, 
inflammatory markers were recorded throughout the study protocol. Erythrocyte 
sedimentation rate (ESR) and C-reactive protein (CRP) were collected at each Remicade 
infusion as part of regular clinical care. Serum markers of inflammation were not shown 
to be affected by vitamin D treatment up to steady-state 25OHD by paired t-test analysis 
for CRP (t, -0.17; CI, -0.04 – 0.04; p= 0.87) and ESR (t, 1.75; CI; -0.29 – 4.25; p= 0.09) 
between baseline levels and those at the fourth infusion. Changes in total 25OHD from 
baseline to steady state also did not appear to correlate with any changes in CRP (R, 0.16; 
CI, -0.13 – 0.42; p= 0.27) or ESR (R, -0.10; CI, -0.37 – 0.19; p= 0.51) over the first 3 
doses (Figure 6). 
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Figure 6. Effect of Vitamin D Status Change on Inflammatory Markers In Vivo. 
Serum inflammatory markers are tracked in IBD patients to monitor chronic 
inflammation. Changes in 25OHD levels from baseline to steady-state was not shown to 
associate with changes in CRP (top) or ESR (bottom). 
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Health Related Quality of Life (IMPACT-III) 
 A quality of life questionnaire (IMPACT-III) was completed by the subject and/or 
a guardian at the time of consent, which was within 8 weeks of a serum 25OHD < 
30ng/mL. Two patients had HRQoL surveys that were not returned or provided within 8 
weeks of qualifying lab date, leaving 59 patients with a reportable HRQoL metric. The 
average IMPACT-III score was 141.1. Self-reported quality of life did not appear to 
relate to vitamin D status, as no significant correlation was found between baseline 
25OHD level and IMPACT-III score (R, 0.03; CI, -0.22 – 0.29; P= 0.79). 
 As of February 1st, 2019, there were 17 subjects who had completed the one-year 
treatment protocol and had provided both starting point and endpoint HRQoL data. 
Paired t-test analysis of IMPACT-III sub-scores, among both dosing groups, did not 
demonstrate any change in IBD related quality of life in patients receiving vitamin D 
treatment over the course of a year (Table 7). 
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Table 7. Change in HRQoL Metric Following One-Year Vitamin D Therapy. A 
standardized pediatric IBD HRQoL Survey was collected once at the time of consent and 
once again at last vitamin D dose, 48-64 weeks later. Paired t-test analysis does not 
suggest a change in IBD related quality of life among pediatric patients receiving interval 
vitamin D supplementation. 
 
IMPACT-III 
[N=17] 
Mean 
Baseline 
Mean 
Endpoint 
Paired t-test 
value 
95% Conf. 
interval 
P-value 
Total 139.6±23.9 146.0±20.5 1.76 
  
-1.35 to 13.62 0.10 
Bowel Symptoms  27.9±5.3 28.7±4.6 1.14 -0.90 to 3.06 0.27 
Systemic Symptoms  11.1±2.7 11.3±2.1 0.41 -0.98 to 1.45 0.69 
Emotional 
Functioning  
27.5±6.6 28.4±6.1 0.56 -2.1 to 3.61 0.58 
Social Functioning  49.8±7.3 51.7±6.7 1.66 -0.48 to 3.85 0.12 
Body Image  10.9±2.5 11.2±2.8 0.33 -1.02 to 1.39 0.74 
Treatments and 
Interventions 
12.5±2.2 13.3±1.4 2.06 -0.02 to 1.79 0.06 
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DISCUSSION 
 This study investigated the safety and efficacy of a novel intervention to manage 
vitamin D deficiency in pediatric patients with IBD. It is also the only study, to our 
knowledge, that provides a profile of confirmed oral vitamin D supplementation over 
multiple doses in a large sample of pediatric patients. In response to the disproportionate 
occurrence of vitamin D deficiency in IBD patients and the inability of prescribed 
supplementation to improve vitamin D status, this intervention used patients’ regularly 
scheduled Remicade infusions as a framework to administer high dose vitamin D therapy. 
The dosing protocol was developed in the hopes of increasing vitamin D therapy 
adherence, in order to increase clinical efficacy, and making supplementation less 
cumbersome for patients and their families. For the purpose of investigation, this protocol 
conveniently allowed for meticulous observation of oral dose administration. 
 
Study Sample Population 
 The investigation was conducted in a sample population of pediatric IBD patients 
with vitamin D deficiency. A sample population in Australia found 57% of children with 
IBD to have 25OHD < 30ng/mL, classified as either vitamin D deficient or insufficient 
(Levin et al., 2011). The current study screened over 500 IBD patients maintained on 
Remicade and found that 51% of patients to have 25OHD levels suggestive of vitamin D 
deficiency or insufficiency between Fall 2016 and Fall 2018. This highlights the 
prevalence of vitamin D deficiency in IBD patients living at temperate latitudes and 
emphasizes the importance of addressing vitamin D insufficiency in these patients. 
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Screening for our study also revealed that less than 10% of patients with vitamin D 
insufficiency or deficiency exhibited liver, kidney, or granulomatous disorders that might 
make high dose vitamin D supplementation inappropriate, and demonstrates that high 
dose vitamin D3 supplementation is a viable vitamin D management option for the vast 
majority of pediatric IBD patients. 
 
Efficacy 
 A sample of vitamin D deficient patients maintained on Remicade for IBD 
symptoms received interval doses of 50,000 IU or 100,000 IU, as determined by 
prescribed Remicade infusion frequency, of vitamin D3 orally for approximately one 
year. Serial monitoring of serum 25OHD levels revealed that, on average, patients 
reached steady state vitamin D levels of 28.9 ng/mL and 33.2 ng/mL, for the 50,000 IU 
dosing group and 100,000 IU dosing groups respectively, after 3 doses, or 4-8 months 
after therapy initiation (Figure 3). Both dosing regimens achieved average 25OHD level 
increases of about 9 ng/mL that were found to be statistically significant. A 
pharmacokinetic study in adults that explored the effect of a single 100,000 IU dose of 
vitamin D3 taken orally found that serum 25OHD levels peaked one week after dose 
administration, where 15 ng/mL increases from baseline were observed, and that 25OHD 
levels, on average remained elevated from baseline for about twelve weeks (Ilahi et al., 
2008). The current study intended to see the effect of supplementation on steady-state 
vitamin D status, rather than peak and trough 25OHD levels, and therefore 25OHD levels 
were measured either 8 weeks, for the 50,000 IU dose group, or 16 weeks, for the 
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100,000 IU dose group, after the most recent dose administration. This shows that 
repeated interval supplementation is capable of more permanently re-establishing 
individuals’ vitamin D level, resulting in increased 25OHD levels even after the response 
to a single dose would have run its course. The current investigation was the first study, 
to our knowledge, to monitor 25OHD level response to repeated administrations high 
dose vitamin D supplementation and therefore it is unknown why 25OHD levels appear 
to plateau and reach a steady-state after three doses. It is possible that, after three or four 
doses, the amount of vitamin D3 simply overwhelmed the vitamin D 25-hydroxylase’s 
ability to convert vitamin D3 to 25OHD, limiting the rate of synthesis, and/or that 
feedback from rising 1,25(OH)2D levels increased the degradation of 25OHD by 25OHD 
24-hydroxylase, increasing rate the metabolism. Both mechanisms would result in a 
steady-state 25OHD level where the rate of 25OHD synthesis is equal to the total rate of 
25OHD metabolism. However, for financial reasons, the current study did not monitor 
vitamin D3 or 24,25(OH)2D levels and was unable to detect any pooling of vitamin D3 or 
changes in vitamin D metabolites that may have resulted from vitamin D3 
supplementation. Further investigation into vitamin D metabolism shifts in vivo in 
response to clinical supplementation are needed to illuminate the primary factor(s) 
influencing steady-state 25OHD levels. This evidence demonstrates the potential for high 
doses of vitamin D3 administered at Remicade infusions to effectively improve pediatric 
patients’ overall vitamin D status. 
 In agreement with the IRB, this intervention study was developed with the 
intention to treat and did not include a non-treatment or placebo control group. Therefore, 
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screening and recruitment was exclusive to patients who exhibited vitamin D 
insufficiency or deficiency. In this sample of vitamin D deficient or insufficient IBD 
patients living in New England, USA, there were about twice as many male subjects, 
three times as many subjects with CD than UC, and the subject population was 70% 
white. However, this demographic profile is not too dissimilar from that of the patients 
treated in BCH’s IBD program, the population from which the sample was drawn, and 
therefore does not point to an increased risk of vitamin D deficiency in any particular 
demographic group. Analysis of baseline vitamin D status did reveal significantly lower 
25OHD levels at baseline in subjects identifying their race as ‘Other’ when compared to 
subjects who chose one of the racial categories. It has been documented by other studies 
that darker skin complexions and identification as “black” are correlated with increased 
risk of vitamin D deficiency and decreased response to vitamin D supplementation, 
respectively (Pappa et al., 2006b; Lewis et al., 2013). However, self-identified race was 
not shown to influence subject response to therapy, as reported by change in 25OHD 
from baseline to steady-state, and subjects’ reported sun sensitivity and tendency to tan 
was not found to correlate with lower baseline 25OHD or decreased response to therapy. 
While the potential for increased risk of vitamin D deficiency in populations with darker 
skin complexion should not be overlooked, the data presented here does not appear to 
suggest that race or skin complexion plays a significant role in the efficacy of vitamin D 
supplementation and is not expected to be a predictor of individual patient response to 
vitamin D therapy. Additionally, the severity of deficiency in baseline 25OHD levels was 
not shown to differ between genders, between CD and UC patients, or with age.  None of 
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these factors were shown to affect steady state 25OHD levels or change in 25OHD from 
baseline to steady-state, and do not suggest that response to high dose therapy differs 
based upon gender, type of IBD, or age. 
A meta-analysis of body composition and vitamin D status found that obese 
individuals, classified by BMI, were 35% more likely to be vitamin D deficient (Pereira‐
Santos et al., 2015). It is thought that obesity may result in low levels of circulating 
25OHD because of the tendency for the fat-soluble vitamin D to sequester in the excess 
adipose tissue in obese patients. This study did not look at relative risk of obese patients 
suffering from vitamin D insufficiency or deficiency as no data was collected from 
vitamin D sufficient patients. In our population of interest, vitamin D deficient children 
and adolescents with IBD, there was no correlation with pretreatment 25OHD levels, 
steady-state 25OHD levels, or change in 25OHD from baseline and BMI.  This suggests 
that BMI should not be a major factor of consideration when assessing the utility of high 
dose vitamin D supplementation in this clinical context. 
 Data on sun exposure and diet were also collected at time of consent and at each 
dose to monitor the effect behavioral changes on vitamin D status. ‘Baseline’ and 
‘Follow-Up’ surveys collected information about how much time subjects spent outside 
on a typical day and how much of their skin was not covered by clothing (Appendices A 
& B). UVB exposure is considered a major factor influencing serum 25OHD levels: one 
study demonstrated that serum 25OHD levels increased 3-fold in subjects with lighter 
skin complexion and almost 2-fold in subjects with darker skin complexion after 12-
weeks of UVB irradiation treatments (Chen et al., 2007) Baseline data did not suggest 
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that spending more time outside correlated with higher 25OHD levels, but rather revealed 
that increasing surface area of exposed skin, i.e. wearing a swimsuit rather than pants and 
a coat, was associated with higher pretreatment 25OHD levels (pages 17-18). The 
absorption of UVB radiation into the skin, which is often blocked by clothing, is required 
for the production of previtamin D3 by 7-dehydrocholesterol reductase in the epidermis. 
It would follow that the effect of time spent in the sun be diminished if most of the skin is 
covered by clothing, whereas increasing the amount of skin exposed to sunlight increases 
the rate of previtamin D3 synthesis for a set duration of time under the sun. However, 
neither of these factors were shown to affect the change in 25OHD in response to vitamin 
D3 therapy and it is thought that the effect of high dose supplementation was significant 
enough to outweigh any effects on 25OHD that may be due to changes in endogenous 
vitamin D synthesis throughout the year. These effects are also considered seasonal as 
seasonal weather patterns dictate how people dress and how often they are outside. 
Another reason for seasonal variation in epidermal previtamin D3 synthesis is the 
incident angle of sunlight hitting the earth. In locations further from the equator, the 
zenith angle of the sun decreases such that less solar radiation reaches the surface during 
the winter months. This means that in northern latitude locations in the United States, like 
Boston or Chicago, there is not enough UVB radiation reaching the earth’s surface for 
any synthesis of vitamin D between November and February (Feldman, Krishnan, & 
Swami, 2013). Although seasonal variation in serum 25OHD levels has been 
demonstrated in populations living at these latitudes (Kroll et al., 2015b), there was no 
observed difference in pretreatment 25OHD level based on the month of treatment 
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initiation, which was within 8 weeks of baseline 25OHD measurement. Additionally, the 
time of year of the first three doses of the study was not shown to influence overall steady 
state 25OHD levels or the change in 25OHD from baseline (Figure 4). Due to the timing 
of the study’s recruitment launch in October 2017 and a period of transition of 
coordinators, where recruitment efforts slowed, there were far more patients enrolled 
between the months of December and March. Perhaps this was also due in part to an 
increased number of patients falling below the study’s deficiency threshold during the 
winter months. Nevertheless, supplementation appeared to improve vitamin D status 
throughout the year and demonstrated the potential to washout these seasonal effects. 
The final source of vitamin D that was considered in order to evaluate changes in 
25OHD was from subjects’ diets. In the U.S. and Canada, milk and dairy products as well 
as many breakfast cereals are fortified with vitamin D; however, the most vitamin D rich 
sources that are readily available to people in North America are oily fish such as salmon, 
trout, cod, and haddock. Farmed salmon and trout contain three times as much vitamin D 
per ounce as cod or haddock, and about five to seven times as much as shellfish (Chen et 
al., 2007). Patients reported their typical consumption frequency of dairy, fortified 
cereals, and fish at their first dose and at each consecutive encounter. Relative 
consumption of vitamin D rich foods, based on patient report, was not shown to influence 
25OHD levels at baseline or affect the response to supplementation from baseline to 
steady state for the 100,000 IU dosing group (Table 4). Effects of vitamin D rich diet 
were undeterminable for the 50,000 IU dosing group due to a small sample of completed 
dietary profiles. An unexpectedly large number of subjects were unsure as to whether or 
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not they consumed vitamin D fortified cereals and had to respond as such. Perhaps the 
vitamin and nutrient contents in fortified foods needs to be better presented on labeling 
and packaging, or consumers need to be more attentive to the nutritional contents of the 
foods they eat. While the responses to dietary habits appeared to range greatly between 
subjects, data on which food brands, sources, and quantity per serving were not collected 
such that dietary vitamin D could be estimated in IU/day for comparison to other studies 
of diet and vitamin D status. However, diets in the U.S. are generally considered to be 
low in vitamin D (Moore, Murphy, Keast, & Holick, 2004). There was no demonstrated 
effect of diet on 25OHD levels and no reason to suggest that dietary changes alone would 
be sufficient to improve vitamin D status in pediatric patients with IBD. 
 
Safety 
 Serum chemistry labs were collected as part of normal clinical care in order to 
identify any unintended side-effects or increased risk associated with high dose therapy. 
For both dosing groups, there was no observed changes in serum calcium, creatinine, or 
BUN over the course of the study (Table 5). In the 100,000 IU dosing group, statistical 
analysis of serum phosphorus levels detected a decrease in subjects’ serum phosphorus 
levels from pretreatment to their fourth vitamin D dose, about 6-8 months into therapy 
(Table 5). This same pattern was not observed in the 50,000 IU dosing group. Typically, 
the active form of vitamin D, 1,25(OH)2D, works to maintain serum phosphorus levels, 
by binding with VDR in the intestinal epithelium and in osteoblasts to increase the 
absorption of dietary phosphorus, mobilize phosphorus stores from mineralized bone, and 
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decrease wasting of phosphorus by the kidneys (Hossein-nezhad & Holick, 2013; 
Fukumoto, 2014). It seems counter-intuitive that increasing serum 25OHD, and 
presumably the amount of 1,25(OH)2D, would then decrease serum phosphorus. 
However, 1,25(OH)2D synthesis and function is closely linked to that of parathyroid 
hormone (PTH) and fibroblast growth factor 23 (FGF23). PTH acts in synergy with 
1,25(OH)2D to mediate phosphorus and calcium transport out of bone and into 
circulation, but also opposes 1,25(OH)2D action in the kidneys by blocking phosphate 
reabsorption and increasing urinary excretion of phosphate. While circulating PTH does 
contribute to decreases in phosphorus, FGF23 is a potent regulator of vitamin D that, in 
response to increased 1,25(OH)2D, inhibits 25OHD 1α-hydroxylase activity and tubular 
resorption of phosphate in the kidneys (Feldman et al., 2013). Therefore, it is probable 
that increases in 1,25(OH)2D, as a result of vitamin D3 supplementation, induced relative 
increases in circulating FGF23 that acted on the kidneys to increase urinary excretion of 
phosphate and decrease serum phosphorus. However, neither PTH nor FGF23 nor 
1,25(OH)2D levels were collected as part of the study due to the expense and difficulty to 
acquire: circulating 1,25(OH)2D is hard to measure because its concentration in plasma is 
.01% that of 25OHD (Feldman et al., 2013) and plasma FGF23 measurements have 
limited clinical utility due to high diurnal variability (Smith et al., 2012). While the 
current investigation detected a dip in serum phosphorus as a result of vitamin D therapy, 
there were no reported cases or manifestations of hypophosphatemia and, from a clinical 
standpoint, the administration of high doses of vitamin D3 is not shown to cause 
significant disturbances or alterations in blood chemistry, most notably calcium and 
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phosphorus. More focused and higher-powered studies than the study conducted here are 
needed to extrapolate how high dose vitamin D supplementation may or may not affect 
phosphorus handling by PTH and FGF23 in vivo. 
 Although not commonly looked at in vitamin D supplementation studies, spot 
urine samples were also collected to regularly monitor hypercalciuria and assess patient 
risk for developing renal stones. Urine calcium-to-creatinine ratios were measured from 
spot urine samples at every other dose and found no overall change in urine calcium-to-
creatinine ratios as a result of the first few high doses or after repeated intervals of high 
dose supplementation (Figure 5). 17% of subjects had at least one spot urine calcium-to-
creatinine ratio found to be elevated over the course of the study, only 5% had elevated 
samples at consecutive encounters, and none of these returned elevated 24-hour urine 
calcium-to-creatinine ratios. Therefore, the elevated calcium-to-creatinine ratios 
measured are most likely a result of the subject having recently eaten a meal. It has been 
demonstrated that calcium to creatinine ratios calculated from spot urine collections do 
not correlate well with those calculated from 24-hour collection and are far less useful at 
identifying hypercalciuria. Such inconsistency in spot urine samples is due to the 
reactionary excretion of calcium by the kidneys in response to increased serum calcium 
directly following a meal, and results in overestimation of urine calcium-creatinine values 
post-prandially and underestimation during fasting (Jones et al., 2012). This investigation 
utilized spot urine collections given the convenience for subjects to provide samples at 
infusions, which are scheduled all throughout the day, and were merely used as a first-
line of observation. The lack of elevated calcium-to-creatinine ratios from 24-hour 
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samples in this study demonstrates that vitamin D3 administered in 50,000 and 100,000 
IU doses does not increase patient risk for hypercalciuria or kidney stones in the short-
term or over repeated doses. 
 Other than a single patient who opted to remove themselves from the study after 
they reported experiencing some nausea after their first dose there were no observed 
adverse events in relation to interval vitamin D therapy nor were there any Remicade 
infusion reactions in subjects while on the vitamin D study. Neuropsychiatric symptoms 
typically reported with vitamin D toxicity are confusion, drowsiness, and apathy 
secondary to hypercalcemia (Marcinowska-Suchowierska, et al., 2018) and it is not 
thought that the nausea symptoms reported were in response to the high dose of vitamin 
D3, especially since the subject had reported experiencing these symptoms with other 
doses of vitamin D and because no other subjects appeared to present similar symptoms 
with the same dose. Perhaps this individual has a sensitivity to ingested vitamin D or has 
a sensitivity/allergy to one of the inactive ingredients in the vitamin D capsule, most 
commonly gelatin. The data from this investigation demonstrates that 50,000 IU and 
100,000 IU doses of oral vitamin D given at four to eight-week intervals does not 
increase risk of hypercalcemia (Table 5) and hypercalciuria (Figure 5) in pediatric 
patients, and overall suggests this dosing regimen to be a minimal risk intervention. 
 
Disease Activity and IBD Symptoms 
 One of the aims of this study was to assess the utility of a novel vitamin D therapy 
regimen as part of the clinical management of IBD in children and adolescents, therefore 
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disease activity scores, inflammatory biomarker levels, and an HRQoL survey were 
collected for each subject and related to 25OHD. Disease activity analysis was separated 
by IBD diagnosis because there exists one standardized disease activity quantification 
tool for CD, the aPCDAI, and one for UC, the PUCAI. For CD patients, baseline 
aPCDAI scores were found to inversely correlate with serum 25OHD, i.e. higher 25OHD 
levels were associated with lower disease activity and less severe symptoms. This 
suggests that vitamin D could play a protective role in CD, or perhaps that increased 
inflammation and more active disease results in physiological and/or behavioral changes 
that influence vitamin D status: malabsorption and decreased appetite due to 
inflammation in the GI tract could markedly reduce the influx of vitamin D from dietary 
sources, or perhaps the pain and fatigue associated with active disease lead to patients 
spending more time inside and out of the sun. These findings are consistent with previous 
work showing that higher 25OHD levels were inversely correlated with intestinal 
inflammation in pediatric CD and UC (Garg et al., 2013). The same relationship was not 
found in patients with UC in this study, as PUCAI scores were shown to be independent 
of 25OHD level at baseline. Disease activity scores were also assessed at the conclusion 
of the study, after about one year on high dose therapy. Statistical analysis of the 
endpoint data collected so far does show a significant change in disease activity scores 
following months of interval supplementation. However, only a handful of subjects have 
completed the protocol and the effect of supplementation on aPCDAI and PUCAI scores 
will not be determined until more subjects reach the one-year endpoint and the sample 
size grows larger. 
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 There is adequate data from murine models and clinical studies in humans that 
circulating 25OHD plays a significant role in immune system regulation in children and 
adults, acting to promote the differentiation and function of regulatory T cells in order to 
subdue inflammation (Yin & Agrawal, 2014b; S. Wu et al., 2015; Looman Kirsten I.M. et 
al., 2017). Patients regularly have ESR and CRP measured as part of their standard IBD 
care at BCH in order to monitor overall inflammatory status. These values were followed 
in study subjects throughout the study, and there was no association found between 
changes in ESR or CRP and change in 25OHD from each of their baseline levels. Similar 
to another study focused on the relationship between vitamin D status and pediatric IBD, 
a correlation was not established between 25OHD levels and clinical markers of systemic 
inflammation (Garg et al., 2013). There continues to be a lack of evidence to support the 
ability of vitamin D to influence inflammatory disease processes in a clinical context. 
Translation from animal models to clinical efficacy is thought to remain difficult because 
of varying threshold values for each of the numerous targets of 1,25(OH)2D in the body. 
In this case, it is thought that the average 9 ng/mL increase in 25OHD was not sufficient 
to significantly alter markers of inflammation or disease processes in CD and UC. 
Perhaps a 25OHD of greater magnitude would induce noticeable shifts in clinical disease 
presentation. 
Analysis of baseline quality of life responses did not suggest any correlation 
between total IMPACT-III scores and 25OHD in a sample of vitamin D deficient 
patients; however, any correlation between IMPACT-III scores and baseline 25OHD 
levels for vitamin D sufficient patients was not investigated in this study. If threshold 
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values for 25OHD and its effect on gastrointestinal disease symptoms are in a range 
above 30 ng/mL, then any correlation between the two would not have been detectable 
with the sample population. As HRQoL responses are only collected twice, once at 
baseline and once more at the 48 to 64-week endpoint, less than one third of subjects 
have paired HRQoL scores. Similar to disease activity index data, paired t test analysis of 
the small sample size so far does not reveal a significant change in the IMPACT-III total 
score, or any of its six sub scores, as a result of 12 months of vitamin D therapy. A 
determinable effect of 25OHD levels on overall patient quality of life will not be found 
until more data has been collected, but currently it is offered that the magnitude of 
25OHD increase was not enough to reveal detectable changes in the IMPACT-III metric. 
 
Conclusions and Future Directions 
 Analysis of an almost complete dataset of subjects receiving high dose vitamin D 
supplementation concurrent with Remicade infusions has shown that oral administration 
of 50,000 IU and 100,000 IU doses of vitamin D3 is a safe and effective method for 
improving 25OHD levels in pediatric IBD patients with vitamin D deficiency. Interval 
dosing was able to achieve steady state 25OHD levels ~30 ng/mL after three doses in 
both dosing groups and maintain 25OHD levels elevated from baseline for about 12 
months. Supplementation was the only factor demonstrated to affect the change in 
25OHD levels throughout the study, suggesting that high dose therapy can overcome 
seasonal dips in vitamin D and absence of vitamin D in the diet. Serum 25OHD levels 
increased an average of 9 ng/mL from baseline to steady-state, but this change in 25OHD 
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level does not appear to be sufficient to have marked effects on IBD symptoms, 
inflammatory markers, or overall quality of life in IBD patients. Higher target vitamin D 
levels may be needed to see clinical improvements relevant to IBD. It is proposed that 
increasing the supplementation dose or frequency should allow for attainment of 25OHD 
levels above 40 ng/mL, which have been shown to be protective against colon cancer ( K. 
Wu et al., 2007; Jenab et al., 2010; McCullough et al., 2018), without substantially 
increasing risk of toxicity or other side-effects. Future investigations on the safety of 
larger doses of vitamin D3 and achievement of higher target 25OHD levels are needed to 
confidently identify the role vitamin D therapy plays in the clinical maintenance of 
pediatric IBD. 
 It has been shown that vitamin D status, both pre- and post-induction, has been 
predictive of IBD response to anti-TNF therapies, such as Remicade. Two studies in 
adult cohorts have suggested that increased 25OHD levels are associated with increased 
likelihood and duration of sustained remission on TNF blockers (Winter et al., 2017; 
Zator et al., 2014).  While the duration of Remicade therapy response was not an 
observed outcome in this study, it was noted that there was no occurrence of adverse 
events of Remicade infusion reactions for subjects while on vitamin D therapy. Similar 
investigations should be run in pediatric populations to better understand the vitamin D’s 
potential role as an adjunct to increase the safety and efficacy of anti-TNF drugs. 
 Finally, this study used regularly scheduled infusions as a framework for 
supplementation and limited our treatment population to those IBD patients maintained 
on a common, but specific, intravenous therapy. As a result, the protocol excluded a large 
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population of IBD patients who are also vitamin D deficient. An amended dosing plan 
should be developed and tested to accommodate IBD patients who do not receive 
Remicade as a maintenance therapy.  
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Follow-Up Survey Case Report Form 
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